WallStSmart
NVCT

Nuvectis Pharma Inc

NASDAQ: NVCT · HEALTHCARE · BIOTECHNOLOGY

$11.06
+3.87% today

Updated 2026-06-04

Market cap
$256.50M
P/E ratio
P/S ratio
EPS (TTM)
$-1.31
Dividend yield
52W range
$6 – $13
Volume
0.1M

Nuvectis Pharma Inc (NVCT) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item202020212022202320242025
Revenue$0.00$149000.00$0.00$0.00$0.00
Revenue growth (YoY)-100.0%
Cost of revenue$12.89M$19.23M$22.90M
Gross profit$-12.89M$-19.09M$-22.90M
Gross margin-12808.7%
R&D$9.54M$13.23M$15.38M$12.92M$18.15M
SG&A$24000.00$3.35M$6.01M$7.52M$6.93M$9.42M
Operating income$-10000.00$-12.89M$-19.23M$-22.90M$-19.85M$-27.57M
Operating margin-12908.7%
EBITDA$-10000.00$-12.89M$-18.94M$-22.26M$-19.00M$-26.44M
EBITDA margin-12708.7%
EBIT$-34000.00$-12.89M$-19.23M$-21.90M$-19.85M
Interest expense$0.00$4000.00$149000.00
Income tax
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%
Net income$-10000.00$-12.89M$-18.79M$-22.26M$-19.00M$-26.44M
Net income growth (YoY)-128760.0%-45.8%-18.5%+14.6%-39.2%
Profit margin-12608.7%

Frequently asked questions

How much free cash flow does NVCT generate?

NVCT produced $-16.01M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is NVCT's balance sheet healthy?

NVCT holds $31.63M in cash and equivalents against — in long-term debt, on $18.41M of shareholder equity. That debt is best read against the cash flow the business throws off each year.